The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta

https://doi.org/10.1016/0006-291X(92)91710-8Get rights and content

Abstract

The purpose of this study was to examine the specificity of the cyclic pentapeptide ETA receptor antagonist BQ-123. BQ-123 competitively antagonized endothelin-1-induced contractions in rabbit aorta, increases in inositol phosphates in cultured rat vascular smooth muscle A10 cells, and binding of [125I]endothelin-1 to the cloned ETA receptor cDNA expressed in Cos 7 cells. In contrast, BQ-123 was a weak antagonist of [125I]endothelin-3 binding to rat cerebellar membranes and to membranes from Cos 7 cells transfected with the cloned ETB receptor cDNA. BQ-123 shifted concentration-response curves in isolated rabbit aorta elicited by angiotensin II, but did not bind to angiotensin II receptors nor affect angiotensin II-induced increases in inositol phosphates. BQ-123 also did not affect contractions induced by KCl or norepinephrine. These data suggest that endothelin may play a role in angiotensin II-induced contractions of rabbit aorta.

References (24)

  • R.J. Secrest et al.

    Life Sci

    (1989)
  • E.R. Martin et al.

    Biochem. Biophys. Res. Commun

    (1989)
  • R. Morishita et al.

    Biochem. Biophys. Res. Commun

    (1989)
  • I. Komuro et al.

    FEBS Lett

    (1988)
  • N. Takuwa et al.

    J. Biol. Chem

    (1989)
  • M. Ihara et al.

    Biochem. Biophys. Res. Commun

    (1991)
  • K.E.J. Dickinson et al.

    Biochem. Biophys. Res. Commun

    (1991)
  • G. Grynkiewicz et al.

    J. Biol. Chem

    (1985)
  • H. Shinyama et al.

    Biochem. Biophys. Res. Commun

    (1991)
  • M. Yanagisawa et al.

    Nature

    (1988)
  • M. Yanagisawa et al.
  • T. Ishikawa et al.

    Am. J. Physiol

    (1988)
  • Cited by (55)

    • New approaches for managing preeclampsia: Clues from clinical and basic research

      2014, Clinical Therapeutics
      Citation Excerpt :

      Along this line, Thaete et al61 recently reported that a small-molecule inhibitor of the ETA receptor antagonist ABT-546 was maternally restricted, with fetal exposure at only ~2% of maternal levels. Likewise, a number of small-peptide–based inhibitors of the ETA receptor have been described which, if stabilized for better pharmacologic parameters and fetal exclusion, could be a potent approach to managing the maternal symptoms of preeclampsia.62 Preeclampsia remains an enigmatic disorder of pregnancy, with an incomplete understanding of its etiology and a lack of therapeutic options for the clinical practitioner.

    • Endothelium-derived vasoactive agents, AT1 receptors and inflammation

      2011, Pharmacology and Therapeutics
      Citation Excerpt :

      In addition, ET-1 treatment of isolated EC stimulates the conversion of Ang I to Ang II via enhancing local ACE activity (Kawaguchi et al., 1991) suggesting that ET-1 and Ang II peptides may have the capacity to increase the quantity of each other. In isolated rabbit aorta ET-1 receptor antagonism resulted in reduction in the vasoconstrictor response to Ang II (Webb et al., 1992). Moreover, in vivo, infusion of Ang II was also shown to enhance levels of ET-1 in the rat in a way that was blocked by ET-1 receptor (Moreau et al., 1997) and AT1R antagonism (d'Uscio et al., 1998), whilst blockade of ET-1 receptors was shown to prevent the hemodynamic changes induced by low (but not high) doses of Ang II (Balakrishnan et al., 1996).

    View all citing articles on Scopus
    View full text